Elisa Oricchio is the Director of the Swiss Institute for Experimental Cancer Research (ISREC) and a professor at EPFL in Lausanne (Switzerland).
She received her Ph.D. in 2008 and did her post-doctoral training at Memorial Sloan Kettering Cancer Center, where she gained expertise in cancer genomics, genetic manipulation of transgenic animal models, and pre-clinical treatment studies.
Currently, research in her lab aims at systematically integrating genomic and functional analyses to identify oncogenic events in cancer and exploit this information for the design of novel therapies
Throughout her career, she has identified oncogenes or tumor suppressor genes as new therapeutic targets or as biomarkers to better classify cancer patients. She has integrated linear cancer genomic analyses with tridimensional analyses of the genome to better understand tumor development and evolution. 

Her work has been recognized with the Blavatnik Award for Young Scientist by the New York Academy of Science, the Lorini Award for Italian Scientist in Cancer Research, and in 2021 she received the Prix Leenaards for Translation Research.

Elisa Oricchio delivered the prestigious Pezcoller Foundation – EACR Translational Cancer Researcher Award Lecture at the EACR 2024 Congress, Rotterdam, June 10. She will also be invited to give a lecture in Trento, Italy, in Autumn 2024 at the Pezcoller Foundation, and will receive a €10,000 honorarium.  

Page updated 17/06/2024
Pezcoller Award Lecture from Elisa Oricchio at the EACR Congress, Rotterdam, 10 June 2024
unchecked checked